| Literature DB >> 31982652 |
Pasquale Linciano1, Gregorio Cullia2, Chiara Borsari1, Matteo Santucci1, Stefania Ferrari1, Gesa Witt3, Sheraz Gul3, Maria Kuzikov3, Bernhard Ellinger3, Nuno Santarém4, Anabela Cordeiro da Silva5, Paola Conti2, Maria Laura Bolognesi6, Marinella Roberti6, Federica Prati6, Francesca Bartoccini7, Michele Retini8, Giovanni Piersanti8, Andrea Cavalli9, Luca Goldoni10, Sine Mandrup Bertozzi10, Fabio Bertozzi11, Enzo Brambilla11, Vincenzo Rizzo11, Daniele Piomelli12, Andrea Pinto13, Tiziano Bandiera11, Maria Paola Costi14.
Abstract
The LIBRA compound library is a collection of 522 non-commercial molecules contributed by various Italian academic laboratories. These compounds have been designed and synthesized during different medicinal chemistry programs and are hosted by the Italian Institute of Technology. We report the screening of the LIBRA compound library against Trypanosoma brucei and Leishmania major pteridine reductase 1, TbPTR1 and LmPTR1. Nine compounds were active against parasitic PTR1 and were selected for cell-based parasite screening, as single agents and in combination with methotrexate (MTX). The most interesting TbPTR1 inhibitor identified was 4-(benzyloxy)pyrimidine-2,6-diamine (LIB_66). Subsequently, six new LIB_66 derivatives were synthesized to explore its Structure-Activity-Relationship (SAR) and absorption, distribution, metabolism, excretion and toxicity (ADMET) properties. The results indicate that PTR1 has a preference to bind inhibitors, which resemble its biopterin/folic acid substrates, such as the 2,4-diaminopyrimidine derivatives.Entities:
Keywords: Anti-parasitic drug discovery; High throughput screening; LIBRA compound library; Pteridine reductase 1
Year: 2020 PMID: 31982652 DOI: 10.1016/j.ejmech.2020.112047
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514